Noribogaine, a polypharmacological
drug with activities at
opioid receptors, ionotropic
nicotinic receptors, and
serotonin reuptake transporters, has been investigated for treatment of
substance abuse-related disorders. Smoking cessation has major benefits for both individuals and society, therefore the aim of this study was to evaluate the potential of
noribogaine for use as a treatment for
nicotine dependence. Adult male Sprague-Dawley rats were trained to self-administer
nicotine intravenous. After initial food pellet training, followed by 26 sessions of
nicotine self-administration training, the rats were administered
noribogaine (12.5, 25 or 50 mg/kg orally),
noribogaine vehicle,
varenicline or saline using a within-subject design with a Latin square test schedule.
Noribogaine dose-dependently decreased
nicotine self-administration by up to 64% of saline-treated rats' levels and was equi-effective to 1.7 mg/kg intraperitoneal
varenicline.
Noribogaine was less efficient at reducing food pellets
self-administration than at
nicotine self-administration, inhibiting the nondrug reinforcing effects of palatable pellets by 23% at the highest dose. These results suggest that
noribogaine dose-dependently attenuates
drug-taking behavior for
nicotine, attenuates the reinforcing effects of
nicotine and is comparable to
varenicline power in that regard. The findings from the present study hold promise for a new
therapy to aid smoking cessation.